GCP
LAB icon

GSA Capital Partners’s Standard BioTools LAB Stock Holding History

GSA Capital Partners’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$977K Buy
1,187,682
+834,211
+236% +$788K 0.06% 513
2026
Q1 		$325K Buy
353,471
+306,205
+648% +$371K 0.02% 1205
2025
Q4 		$61K Buy
+47,266
New +$63.5K 0.01% 1564
2025
Q3 		– Sell
-306,487
Closed -$368K – 1892
2025
Q2 		$368K Sell
306,487
-302,169
-50% -$335K 0.03% 1133
2025
Q1 		$657K Buy
608,656
+478,922
+369% +$672K 0.06% 608
2024
Q4 		$227K Buy
+129,734
New +$242K 0.02% 1354
2022
Q1 		– Sell
-101,494
Closed -$398K – 1632
2021
Q4 		$398K Buy
101,494
+57,589
+131% +$270K 0.05% 748
2021
Q3 		$289K Buy
+43,905
New +$289K 0.03% 1045
2021
Q2 		– Sell
-105,852
Closed -$478K – 1473
2021
Q1 		$478K Buy
105,852
+63,908
+152% +$351K 0.08% 379
2020
Q4 		$252K Sell
41,944
-40,959
-49% -$269K 0.04% 842
2020
Q3 		$616K Buy
+82,903
New +$572K 0.1% 283
2019
Q2 		– Sell
-61,910
Closed -$823K – 1597
2019
Q1 		$823K Buy
+61,910
New +$653K 0.08% 392
2014
Q1 		– Sell
-7,020
Closed -$269K – 1691
2013
Q4 		$269K Buy
+7,020
New +$207K 0.02% 1280

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

GSA Capital Partners's LAB Position: Q2 2026 in Review

GSA Capital Partners increased its Standard BioTools (LAB) stake by 236% in Q2 2026, buying an estimated $788K and bringing the position to 1,187,682 shares worth $977K. The position accounts for 0.06% of the portfolio, ranked #513.

GSA Capital Partners first reported a position in LAB in Q4 2013 and has held it in 13 quarters since. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • GSA Capital Partners held 1,187,682 shares of Standard BioTools worth $977K as of Q2 2026.
  • GSA Capital Partners bought 834,211 Standard BioTools shares in Q2 2026, an estimated $788K.
  • Standard BioTools made up 0.06% of GSA Capital Partners's portfolio in Q2 2026, its #513 holding.
  • GSA Capital Partners first reported a position in Standard BioTools in Q4 2013 and has held it in 13 quarters since.
  • 144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.